CHURCHILL MANAGEMENT Corp Has $21.02 Million Position in Boston Scientific Corporation $BSX

CHURCHILL MANAGEMENT Corp cut its stake in Boston Scientific Corporation (NYSE:BSX) by 0.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 195,676 shares of the medical equipment provider’s stock after selling 1,016 shares during the quarter. CHURCHILL MANAGEMENT Corp’s holdings in Boston Scientific were worth $21,018,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Boston Scientific by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider’s stock worth $13,577,311,000 after purchasing an additional 1,697,945 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Boston Scientific by 18.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider’s stock valued at $1,070,387,000 after buying an additional 1,664,108 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in Boston Scientific by 161.9% in the first quarter. Assenagon Asset Management S.A. now owns 2,485,696 shares of the medical equipment provider’s stock worth $250,757,000 after buying an additional 1,536,663 shares during the last quarter. Swedbank AB increased its holdings in Boston Scientific by 114.5% in the second quarter. Swedbank AB now owns 2,819,249 shares of the medical equipment provider’s stock worth $302,816,000 after buying an additional 1,505,019 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in Boston Scientific by 10.8% during the first quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock valued at $1,426,779,000 after acquiring an additional 1,383,524 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the sale, the executive vice president owned 23,600 shares in the company, valued at approximately $2,469,268. This trade represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of Boston Scientific stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $106.03, for a total value of $424,120.00. Following the sale, the director directly owned 18,479 shares in the company, valued at approximately $1,959,328.37. This trade represents a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock valued at $17,972,457 in the last quarter. Company insiders own 0.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on BSX shares. UBS Group increased their price target on shares of Boston Scientific from $130.00 to $135.00 and gave the stock a “buy” rating in a research note on Thursday, July 24th. Jefferies Financial Group reiterated a “hold” rating on shares of Boston Scientific in a report on Monday, July 21st. Barclays raised their target price on Boston Scientific from $125.00 to $133.00 and gave the company an “overweight” rating in a report on Thursday, July 24th. Raymond James Financial boosted their price target on Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a research report on Thursday, July 24th. Finally, Canaccord Genuity Group increased their price objective on Boston Scientific from $131.00 to $132.00 and gave the company a “buy” rating in a report on Wednesday. Three analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, Boston Scientific currently has an average rating of “Buy” and an average price target of $120.67.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $95.78 on Thursday. The company has a market cap of $141.91 billion, a price-to-earnings ratio of 57.01, a PEG ratio of 2.35 and a beta of 0.61. The business has a 50 day moving average price of $103.30 and a 200 day moving average price of $102.08. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a twelve month low of $80.64 and a twelve month high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The company had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the previous year, the business posted $0.62 EPS. The company’s revenue for the quarter was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.